Sigrun Thorsteinsdottir, MD, PhD^1,2, Gauti Kjartan Gislason, MSc^1*, Thor Aspelund, PhD^3*, Sæmundur Rögnvaldsson, MD^4*, Jon Thorir Thorir Oskarsson^1*, Iris Petursdottir^1*, Jon Kristinn Sigurdsson^1*, Gudrun Asta Sigurdardottir^1*, Asdis Rosa Thordardottir^1*, Brynjar Vidarsson, MD⁵, Pall Torfi Onundarson, MD⁵, Bjarni Agnar Agnarsson, MD^5*, Margret Sigurdardottir, MD^5*, Ingunn Thorsteinsdottir, MD, PhD^5*, Isleifur Olafsson, MD, PhD^5*, Elias Eythorsson, MD, PhD^5*, Asbjorn Jonsson, MD^5*, Petros Kampanis, PhD^6*, Malin Hultcrantz, MD PhD⁷, Brian G.M. Durie, MD⁸, Thorvardur Jon Love, MD, PhD^1*, Stephen Harding, PhD⁹, Ola Landgren, MD¹⁰ and Sigurdur Yngvi Kristinsson, MD, PhD^1,5

¹Faculty of Medicine, University of Iceland, Reykjavik, Iceland
²Department of Hematology, Rigshospitalet, Copenhagen, Denmark
³Public Health Sciences, University of Iceland, Reykjavik, Iceland
⁴Faculty of Medicine, University of Iceland, Reykjavík, Iceland
⁵Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland
⁶Binding Site Group Ltd., Birmingham, United Kingdom
⁷Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁸Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA
⁹The Binding Site Inc., Birmingham, United Kingdom
¹⁰Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami

Habib El-Khoury, MD^1,2, Jean-Baptiste Alberge, PhD^1,2,3*, Hadley Barr^1,2*, Ciara Murphy^1,2*, D.J. Sakrikar, PhD^4*, Tara Krause, MSc^4*, David Barnidge, PhD^4*, Mark Bustoros, MD⁵, Houry Leblebjian, PharmD, BCOP^6*, Annie Cowan, BS^1,7*, Maya Davis, BA^1,2*, Julia Amstutz^1,2*, Jacqueline Perry, MPH^1,2*, Cody J. Boehner, BS^1,2*, Elizabeth D. Lightbody, PhD^1,2*, Tarek H Mouhieddine, MD^1,8,9, Romanos Sklavenitis-Pistofidis, MD^2,3,10, Mark C Perkins, PhD^11*, Stephen Harding, PhD¹¹, Prashant Kapoor, MD¹², Clifton C. Mo, MD^1,2, David L. Murray, MD, PhD^13*, Ivan M. Borrello, MD¹⁴, Gad Getz, PhD^3,15,16*, Timothy R Rebbeck, PhD^1,17*, Catherine R. Marinac, PhD^1,17,18 and Irene M. Ghobrial, MD^1,2,3,18

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Harvard Medical School, Boston, MA
³Broad Institute of MIT and Harvard, Cambridge, MA
⁴The Binding Site Inc., Rochester, MN
⁵Division of Hematology & Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
⁶Department of Pharmacy, Dana-Farber Cancer Institute, Boston, MA
⁷Alix School of Medicine, The Mayo Clinic, Rochester, MN
⁸Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
⁹Harvard Medical School, Cambridge, MA
¹⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA
¹¹The Binding Site Inc., Birmingham, United Kingdom
¹²Division of Hematology, Mayo Clinic, Rochester, MN
¹³Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
¹⁴Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
¹⁵Center for Cancer Research, Massachusetts General Hospital, Boston, MA
¹⁶Cancer Center and Department of Pathology, Massachusetts General Hospital, Boston, MA
¹⁷Harvard T.H. Chan School of Public Health, Boston, MA
¹⁸The Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA

Giovanni Palladini¹, Stefan Schönland^2*, Giampaolo Merlini^1*, Paolo Milani, MD, PhD¹, Arnaud Jaccard^3*, Frank Bridoux, MD^4*, Meletios A. Dimopoulos, MD⁵, Sriram Ravichandran, MBBS, MRCP, FRCPath^6*, Ute Hegenbart, MD^2*, Wilfried Roeloffzen^7*, M. Teresa Cibeira, MD, PhD^8*, Hermine Agis, MD⁹, Monique C. Minnema, MD¹⁰, Rui Bergantim^11*, Roman Hajek, MD, PhD¹², Cristina João, MD, PhD, MSc^13*, Alexandros Leonidakis, PhD^14*, Giorgos Cheliotis, MSc^14*, Pieter Sonneveld¹⁵, Efstathios Kastritis, MD^5* and Ashutosh D. Wechalekar, MBBS MD⁶

¹Amyloidosis Research and Treatment Center, Department of Molecular Medicine, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
²Medical Department V, Amyloidosis Center Heidelberg, University of Heidelberg, Heidelberg, Germany
³National Amyloidosis Center and Hematology Unit, CHU Limoges, Limoges, France
⁴Nephrology Unit, CHU Poitiers, Poitiers, France
⁵Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
⁶National Amyloidosis Centre, University College London, London, United Kingdom
⁷Amyloidosis Centre of Expertise, Department of Internal Medicine, University Medical Center Groningen, Groningen, Netherlands
⁸Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic, Barcelona, Spain
⁹Department of Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna, Austria
¹⁰Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands
¹¹Department of Hematology, Hospital São João, Porto, Portugal
¹²Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
¹³Department of Hematology, Champalimaud Centre for the Unknown, Lisbon, Portugal
¹⁴Health Data Specialists, Dublin, Ireland
¹⁵Cancer Institute, Erasmus MC, Rotterdam, Netherlands

Sæmundur Rögnvaldsson, MD^1*, Elias Eythorsson, MD, PhD^2*, Sigrun Thorsteinsdottir, MD, PhD^3,4, Brynjar Vidarsson, MD⁵, Pall Torfi Onundarson, MD⁵, Bjarni Agnar Agnarsson, MD^5*, Margret Sigurdardottir, MD^5*, Ingunn Thorsteinsdottir, MD, PhD^5*, Isleifur Olafsson, MD, PhD^5*, Hrafnhildur Linnet Runolfsdottir, MD, PhD^2*, Dadi Helgason, MD, PhD^2*, Arna Emilsdóttir, MD^2*, Aron H Bjornsson, MD^2*, Gudrun Kristjansdottir, MD^2*, Asdis Rosa Thordardottir^3*, Olafur Skuli Indridason, MD, MHS^1,6*, Asbjorn Jonsson, MD^7*, Gauti Kjartan Gislason, MSc^3*, Andri Olafsson^3*, Hlif Steingrimsdottir, MD^8*, Petros Kampanis, PhD^9*, Malin Hultcrantz, MD PhD¹⁰, Brian G.M. Durie, MD¹¹, Stephen Harding, PhD¹², Ola Landgren, MD¹³, Thorvardur Jon Love, MD, PhD^3*, Runolfur Palsson, MD^1,5* and Sigurdur Y Kristinsson, MD, PhD^3,6

¹Faculty of Medicine, University of Iceland, Reykjavík, Iceland
²Landspítali - The National University Hospital of Iceland, Reykjavík, Iceland
³Faculty of Medicine, University of Iceland, Reykjavik, Iceland
⁴Department of Hematology, Rigshospitalet, Copenhagen, Denmark
⁵Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland
⁶Landspítali - The University Hospital of Iceland, Reykjavik, Iceland
⁷Akureyri Hospital, Akureyri, Iceland
⁸Landspitali - National University Hospital of Iceland, Reykjavík, Iceland
⁹Binding Site Group Ltd., Birmingham, ENG, United Kingdom
¹⁰Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹¹Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA
¹²The Binding Site Inc., Birmingham, United Kingdom
¹³Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami

Andrew Staron, MD¹, Luke Zheng, BS^2*, Gheorghe Doros, PhD^2*, Lawreen H Connors, PhD^3* and Vaishali Sanchorawala, MD⁴

¹Amyloidosis Center, Boston Medical Center, Boston, MA
²Department of Biostatistics, Boston University School of Public Health, Boston, MA
³Amyloidosis Center, Boston University School of Medicine, Boston, MA
⁴Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA

Sigurdur Y Kristinsson, MD, PhD^1,2, Sæmundur Rögnvaldsson, MD^3*, Sigrun Thorsteinsdottir, MD, PhD^1,4, Elin Ruth Reed^5*, Jon Thorir Thorir Oskarsson^1*, Iris Petursdottir^1*, Gudrun Asta Sigurdardottir^1*, Brynjar Vidarsson, MD⁶, Pall Torfi Onundarson, MD⁶, Bjarni Agnar Agnarsson, MD^6*, Margret Sigurdardottir, MD^6*, Ingunn Thorsteinsdottir, MD, PhD^6*, Signy Vala Sveinsdottir, MD PhD^7*, Robert Palmason, MD^7*, Isleifur Olafsson, MD, PhD^6*, Fridbjorn Sigurdsson, MD^8*, Asdis Rosa Thordardottir^1*, Elias Eythorsson, MD, PhD^6*, Asbjorn Jonsson, MD^6*, Runolfur Palsson, MD^6*, Olafur Skuli Indridason, MD, MHS^2*, Gauti Kjartan Gislason, MSc^1*, Andri Olafsson^1*, Jon Kristinn Sigurdsson^1*, Ingigerdur Solveig Sverrisdottir, MD, BSc^5*, Maria Soffia Juliusdottir^9*, Gudlaug Katrin Hakonardottir^5*, Hlif Steingrimsdottir, MD^10*, Ragnar Danielsen^7*, Petros Kampanis, PhD^11*, Malin Hultcrantz, MD PhD¹², Brian G.M. Durie, MD¹³, Stephen Harding, PhD¹⁴, Ola Landgren, MD¹⁵ and Thorvardur Jon Love, MD, PhD^1*

¹Faculty of Medicine, University of Iceland, Reykjavik, Iceland
²Landspítali - The University Hospital of Iceland, Reykjavik, Iceland
³Faculty of Medicine, University of Iceland, Reykjavík, Iceland
⁴Department of Hematology, Rigshospitalet, Copenhagen, Denmark
⁵University of Iceland, Reykjavik, Iceland
⁶Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland
⁷Landspitali University Hospital, Reykjavik, Iceland
⁸Akureyri Hospital, Akureyri, Iceland
⁹Jessenius faculty of medicine, Martin, Slovakia
¹⁰Landspitali - National University Hospital of Iceland, Reykjavík, Iceland
¹¹Binding Site Group Ltd., Birmingham, United Kingdom
¹²Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹³Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA
¹⁴The Binding Site Inc., Birmingham, United Kingdom
¹⁵Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami